Navigation Links
Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Date:6/6/2008

"We are choosing not to advance the SYI-2074 program in the very competitive area of acute coronary syndrome at this time, in the absence of stronger surrogate markers of efficacy," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics.

"We are pleased to have established correlation between increased plasma isoprostanes and haptoglobin type, as we believe this further validates the biology underlying our proprietary haptoglobin test. Haptoglobin typing has been used in studies that have evaluated more than 20,000 patients, and researchers have demonstrated that Hp2-2 patients with diabetes are at high risk for myocardial infarction, heart failure and stroke. To that end, our diagnostic test is on track to be available commercially in the second quarter of 2009. Further, we are planning to submit a kit measuring CML (carboxy-methyl-lysine), another increasingly well-validated, cardiovascular biomarker, for FDA marketing clearance in 2009," Dr. Berkowitz continued. "We are also moving forward with our alagebrium program, which began enrollment last month in a Phase 2 study for diastolic heart failure in Haptoglobin 2-2 diabetic patients, which complements a second Phase 2 study in systolic heart failure, begun last November and almost half enrolled."

About the Studies

Trial 201 was a Phase 2, placebo-controlled, dose-escalation study in which patients with diabetes and Hp2-2 were given SYI-2074 at 20, 40 or 80mg or placebo three times daily for 28 days. The study evaluated the impact of these doses on inflammatory biomarkers, and the quality and quantity of their cholesterol. Results found that SYI-2074 demonstrated improvement in some but not all of these biomarkers.

Trial 201a was a Phase 2, placebo-controlled sub-study of Trial 201. Patients with diabetes, meeting enrollment criteria for Trial 201 were tested for haptoglobin type. Patients with Hp2-2 or Hp1-1 were evaluated for baseline leve
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
2. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
3. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
6. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne Medical ... transport services, has been selected by Inc. Magazine ... in America. Photo - ... 500|5000 list identifies successful, privately-held companies with the ... Medical Response, one of only two ambulance companies ...
(Date:9/15/2014)... , Sept. 15, 2014  Catalist-listed QT Vascular Ltd. ... a developer and manufacturer of minimally invasive medical devices ... announce that the Group has enrolled the first European ... . Multiple patients have already been enrolled in ... Auckland City Hospital, in Auckland, New Zealand ...
(Date:9/15/2014)... NEW YORK , Sept. 15, 2014 /PRNewswire/ ... together under one roof Saturday to learn, interact ... treatments at New York City,s first Lupus Trials Fair ... (LRI) and the S.L.E. Lupus Foundation . ... NYC,s leading institutions -- sharing experiences, ideas and ...
Breaking Medicine Technology:MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3
(Date:9/16/2014)... Syracuse, NY (PRWEB) September 16, 2014 ... HearStrong Champion Danielle Strassle at the 2014 Buffalo Bills ... in Buffalo, NY. , Bills legend and NFL ... , assisted the foundation in honoring Strassle for her ... and professional goals and inspire others in her community ...
(Date:9/16/2014)... Online retailer Kettlebell Kings has announced that ... kettlebell purchases in their online store. The company wants ... with this effective workout method that is quickly gaining ... carries a variety of kettlebell brands as well as ... , “We’ve seen for ourselves how effective kettlebells ...
(Date:9/16/2014)... Yellow Spings, OH (PRWEB) September 16, 2014 ... the Master of Arts in Clinical Mental Health ... offering joins a growing list of programs offered through ... the spring semester starting January 2015. , "Antioch University ... a strong reputation in the field and a track ...
(Date:9/16/2014)... Issaquah, WA (PRWEB) September 16, 2014 ... of medical equipment and supplies and a veteran-owned ... lines for medical professionals-- Jant Pharmacal Corporation, Nipro ... is committed to providing its customers the best, ... serve its current customers, and in an effort ...
(Date:9/16/2014)... The Living Ethics lecture series returns ... on what it means to live in an ethically ... and thought-provoking topics. , “The Museum’s job is to ... at their world differently. The Living Ethics series’ ... truly enlightening dialogue,” says Richard Conti, Chief Wonder Officer, ...
Breaking Medicine News(10 mins):Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2Health News:Antioch University Launches Online Master’s Degree Program in Clinical Mental Health Counseling 2Health News:Expanding Community Vision at the Science Museum of Virginia 2
... A recent study finds that, TACE inhibitors currently developed ... control proliferation of tumor cells. TACE is// strongly present ... to current therapies. ,TACE (tumor necrosis factor-alpha-converting ... pair of ligands, called Amphiregulin and TGF-alpha, from the ...
... states have registered a leap in the number of dengue ... authorities fearing that the mosquito-borne// disease could further spread due ... ,The north-eastern state of Kelantan registered the highest jump, from ... cases in the first week of January. ...
... and Drug Administration has given the go-ahead to the ... otherwise called fat loss,// occurring in patients with AIDS ... assist in the manufacture of collagen. ,To ... on a study of 100 HIV patients suffering facial ...
... worried about the lack of natural B vitamin "folate" in ... has linked the inadequacy of this vitamin to birth defects ... to breads and cereals being supplemented with folic acid. This ... nation-wide study, undertaken between 1999 and 2004 showed that more ...
... by Jane Carlton, Ph.D., a parasite specialist and an associate ... University// School of Medicine, have successfully decoded the genome of ... STD that usually affects both men and women. ... of the journal Science. ,Moreover, this 4-year ...
... to a British Muslim scholar a special and specific health ... of Edinburgh University// believes that this could hold the key ... ,While sharing his thoughts in the British Medical Journal, professor ... realize this need and bring about a change in the ...
Cached Medicine News:Health News:A New Strategy to Control Breast Cancer 2Health News:Mosquito-borne Dengue Disease on the Rise in Five Malaysian States 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: